Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Carbidopa/Levodopa/Entacapone
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00601978
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 358
- Registration Number
- NCT00600886
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
🇺🇸Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv., Baltimore, Maryland, United States
🇺🇸University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes, Ann Arbor, Michigan, United States
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
- Conditions
- Transfusional Iron OverloadTransfusional Hemosiderosis
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 197
- Registration Number
- NCT00600938
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT00600275
- Locations
- 🇺🇸
Nevada Cancer Center, Las Vegas, Nevada, United States
🇨🇦Princess Margaret Hospital, Toronto, Canada
🇪🇸Novartis Investigative Site, Barcelona, Spain
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT00584740
- Locations
- 🇩🇪
Novartis Investigative Site, Stuttgart, Germany
Effect of AQW051 in Patients With Memory Impairment
- Conditions
- Mild Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT00582855
- Locations
- 🇬🇧
Novartis Investigator Site, Swindon, United Kingdom
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
- Conditions
- Recurrent Hepatitis C
- Interventions
- Drug: CsA-TAC (standard Treatment)
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT00582738
- Locations
- 🇦🇷
Novartis Investigative site, Buenos Aires, Argentina
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
- Conditions
- Pulmonary Fibrosis Secondary to Systemic Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00581997
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
- Conditions
- Chemotherapy-induced Diarrhea
- Interventions
- Other: Standard Treatment
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT00582426
- Locations
- 🇧🇷
Biocâncer, Belo Horizonte, Brazil
🇧🇷Hospital Sao Lucas- Faculdade de Medicina da PUCRS, Porto Alegre, Brazil
🇧🇷Clínica AMO, Salvador, Brazil
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients
- Conditions
- Heart Transplantation
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT00574743
- Locations
- 🇦🇷
Argentina, Buenos Aires, Argentina
🇨🇦Novartis Investigative, Edmonton, Alberta, Canada
🇦🇷Site 1: X5000BJH, Cordoba, Argentina